November 05, 2025 a 04:38 pm
DGX: Analysts Ratings - Quest Diagnostics Incorporated
Quest Diagnostics Incorporated has been a staple in the diagnostic testing industry, providing critical services globally. Over recent months, analysts have largely maintained a conservative stance, with a predominant lean towards "Hold" and "Buy" ratings. This trend reflects a cautious optimism about the company's growth potential amid a competitive landscape and evolving healthcare needs.
Historical Stock Grades
The following table illustrates the latest ratings for Quest Diagnostics (DGX) as of November 2025, showing a mix of "Strong Buy," "Buy," and "Hold" recommendations. The score bar visually represents the consensus.
| Rating | Number | Score Bar |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 7 | |
| Hold | 10 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment development
Throughout the year, there has been a noticeable shift in sentiment with a stable preference for “Hold” ratings. As the healthcare sector adapts to dynamic changes, analysts are generally taking a balanced approach.
- Increased “Hold” ratings reflect wary optimism in market conditions.
- A gradual decrease in “Strong Buy” recommendations suggests limited immediate catalysts for aggressive growth.
- No "Sell" or "Strong Sell" ratings highlight an absence of significant negative sentiment.
Percentage trends
The shifts in analysts' ratings percentages indicate prudent adjustments in market expectations. The predominant "Hold" ratings underscore a phase of evaluation and risk management typically seen during market fluctuations.
- The percentage of "Strong Buy" ratings fell as the stock stabilized in a competitive market.
- "Buy" recommendations remained steady, indicating confidence in long-term potential amidst short-term volatility.
- A consistent reduction in negative forecasts, with no "Sell" grades recorded recently, aligns with a stable outlook.
Latest Analyst Recommendations
Recent analyst activities demonstrate a general consensus on maintaining prior recommendations, reflecting a stable evaluation of Quest Diagnostics’ market position.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-10-27 | Neutral | Neutral | Piper Sandler |
| 2025-10-22 | Equal Weight | Equal Weight | Barclays |
| 2025-10-22 | Hold | Hold | Truist Securities |
| 2025-10-21 | Buy | Buy | Jefferies |
| 2025-10-21 | Outperform | Outperform | Leerink Partners |
Analyst Recommendations with Change of Opinion
Adjustments in analyst recommendations reflect nuanced shifts in market perspectives, often prompted by regulatory changes, economic outlooks, or quarterly performances.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-08-25 | Neutral | Outperform | Baird |
| 2025-03-04 | Neutral | Buy | Citigroup |
| 2025-01-06 | Outperform | Market Perform | Leerink Partners |
| 2024-12-17 | Overweight | Equal Weight | Morgan Stanley |
| 2024-10-23 | Outperform | Neutral | Baird |
Interpretation
The ratings for Quest Diagnostics suggest an overall cautious optimism among analysts. While there are no significant adverse views, the overwhelming number of "Hold" and "Buy" ratings imply stable, moderate growth prospects amid economic uncertainties. This sentiment portrays analysts' tendencies to await clearer market signals before making bold adjustments. Although some changes indicate slight downgrades, the absence of "Sell" ratings offers reassurance against immediate downturn concerns.
Conclusion
Quest Diagnostics Incorporated is positioned in a stable segment of the healthcare industry, reflected in the consistent "Hold" and "Buy" ratings from analysts. The decrease in "Strong Buy" ratings and increase in "Hold" recommendations signify a cautious approach driven by market uncertainties and the company's steady performance. As the market evaluates potential macroeconomic impacts, analysts remain attentive to growth signals or policy changes that could influence future ratings. Overall, the current sentiment suggests stability with minor variances rather than abrupt market shifts, providing opportunities for observation and potential re-evaluation.